Comparison
Glutathione vs PT-141
Side-by-side of Glutathione and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Glutathione
Glutathione (GSH) is the body's primary intracellular antioxidant. Oral supplementation has variable bioavailability; sublingual, liposomal, and IV forms.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
Glutathione
- •Body's primary intracellular antioxidant; tripeptide of glutamate, cysteine, glycine
- •Oral bioavailability poor; sublingual, liposomal, IV more reliable
- •Richie 2014 trial showed body GSH store increases at 250-1000 mg/day for 6 months
- •NAC supplementation often more cost-effective indirect strategy
- •Modest signals in NAFLD, skin aging, immune support; weak in cardiovascular
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | Glutathione | PT-141 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | GSH, L-glutathione, reduced glutathione | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 0.5 | 2.7 |
| Typical dose (mg) ↗ | 500 | 1.75 |
| Dosing frequency | daily, often divided | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral, sublingual, intravenous | subcutaneous |
| Onset (hr) | 1 | 0.75 |
| Peak (hr) | 2 | 1.5 |
| Molecular weight | 307.32 | 1025.18 |
| Molecular formula | C10H17N3O6S | C50H68N14O10 |
| Mechanism | Tripeptide antioxidant; substrate for glutathione peroxidase (H2O2 reduction), GST (xenobiotic conjugation), glutaredoxin (redox signaling). GSH:GSSG ratio is the central cellular redox indicator. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | OTC dietary supplement | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Insufficient data at supplemental doses; endogenous compound is safe | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | 70-18-8 | 189691-06-3 |
| PubChem CID | 124886 | 9941379 |
| Wikidata | Q116907 | Q422059 |
Safety profile
Glutathione
Common side effects
- mild GI upset
Contraindications
- asthma (IV / inhaled forms specifically)
- active chemotherapy without oncologist guidance
Interactions
- chemotherapy agents: theoretical interference with GSH-depletion-dependent agents(moderate)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
Glutathione comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is liver function, pick Glutathione.
- → If your priority is healthspan extension, pick Glutathione.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you want to avoid research-only / gray-market sourcing, Glutathione is the more accessible choice.
Default choice: Glutathione. Lower friction to source, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Glutathione and PT-141?
Glutathione and PT-141 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Glutathione or PT-141?
Glutathione half-life is 0.5 hours; PT-141 half-life is 2.7 hours.
Can you stack Glutathione with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper